with core-specific IgG levels >10 Ag/ml at the onset of septicemia had better survival than those with levels <10 ug/ml (79 vs. 14%, P < 0.001), and patients with core-specific IgM levels >30 ,ug/ml had better survival than those with levels <30 ;g/ml (81 vs. 44%, P = 0.01).
In comparison, patients with total IgG levels >1,000 mg/dl also had better survival than those with levels <1,000 mg/dl (82 vs. 42%, P = 0.01), while those with total IgM levels >150 mg/dl showed somewhat less improvement in survival compared with those with levels <150 mg/dl (71 vs. 50%, P = 0.12). Core-specific IgM was highly correlated with core-specific IgG (r = 0.52), but not with type-specific anti-lipopolysaccharide (r = 0.13) or anti-toxin A (r = 0.12) antibodies, or with total IgG (r = 0.28) or IgM (r = 0.31). In contrast, core-specific IgG correlated somewhat more closely with type-specific antibodies (r = 0.36), and with total IgG (r = 0.51) and IgM (r = 0.52). Stepwise linear discriminant analysis indicated that type-specific antibody levels were the best predictor of outcome, among those antibodies examined, followed by anticore 1gM. Although anti-core IgG, anti-toxin A, and total IgG levels all correlated individually with survival, none augmented the prognostic power of type-specific antibodies in combination with anti-core IgM, which together predicted outcome accurately 73.5% of the time. Host factors not significantly associated with anticore antibody levels included rapidly fatal underlying disease, age, sex, leukopenia, and prior treatment with cytotoxic drugs. In contrast, prior steroid therapy was associated with low levels of both core-specific IgG and IgM (P < 0.05). These data suggest cross-protective activity against P. aeruginosa septicemia of naturally occurring antibodies to the endotoxin core of E. coli.
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Anti-core antibodies, particularly of the IgM isotype, appear to augment the more specific protective immunity engendered by antibodies to the O-specific side chains of Pseudomonas lipopolysaccharides. This crossprotective immunity likely applies to other Gram-negative pathogens as well.
INTRODUCTION
Lipopolysaccharides (endotoxins) are major cell wall constituents of Gram-negative bacteria. They appear to play an important pathophysiologic role in Gramnegative septicemia, and also serve as targets for host antibodies.
In general, bacterial lipopolysaccharides consist of a highly variable outer region composed of repeating oligosaccharide units ("O-specific side chains"), and a relatively constant core region containing a small number of sugars including the trisaccharide 2-keto-3-deoxyoctonate (KDO)' and the biologically active lipid A moiety (1, 2) . This core region is sometimes referred to as core glycolipid or endotoxin core. Antibodies to O-specific side chains in the variable outer region of lipopolysaccharides are species-and typespecific, with their protective activity derived from their ability to promote the phagocytosis and killing of infecting organisms by host phagocytes (3) . In contrast, antibodies directed toward the lipid A-containing inner core region are broadly cross-reactive among a wide variety of Gram-negative bacteria (4-7) and are thought to act by neutralizing the biological activities of endotoxin (8) (9) (10) (11) .
Much of our knowledge of the immunochemistry of lipopolysaccharides has been derived from the study of rough mutant strains of Salmonella (1) and Escherichia coli (12) . The lipopolysaccharides from these strains lack O-specific side-chains and varying portions of their outer core structure, yet retain their relatively homogeneous and weakly immunogenic inner core structures. A strategy has evolved over recent years to utilize such rough mutant strains as cross-protective immunogens in Gram-negative septicemia. One such strain, the E. coli J5 mutant (13) , lacks the enzyme uridine diphosphate (UDP)-galactose 4-epimerase and is therefore unable to incorporate galactose into its lipopolysaccharide. The endotoxin core structure of the J5 mutant consists only of lipid A, KDO, heptose, glucose, and N-acetylglucosamine (13, 14) . Immunization of experimental animals with this organism in-'Abbreviations used in this paper: ELISA, enzyme-linked immunosorbent assay; KDO, 2-keto-3-deoxyoctonate; UDPgalactose 4-epimerase, uridine diphosphate-galactose 4 (20) . The mixture was then cooled to 4°C, centrifuged at 10,000 rpm for 10 min, the aqueous phase saved, and the phenol phase reextracted with an equal volume of water as described above. The phenol phase and denatured protein at the phenol-water interface were discarded and the lipopolysaccharide-containing aqueous phases combined. The lipopolysaccharide suspension was then placed in a separatory funnel, extracted with anhydrous diethyl ether (2:1 ratio of ether to lipopolysaccharide suspension), and the aqueous phase saved. Water was added to the ether phase in the amount removed, the mixture shaken, and the aqueous phase removed. The combined aqueous phases were reextracted overnight with additional ether. Excess ether was removed from the final aqueous phase by bubbling nitrogen through the solution. RNase (type II-A, Sigma Chemical Co., St. Louis, MO) was added to the lipopolysaccharide suspension at a concentration of 2 Kunitz units/ml. The mixture was then dialyzed at room temperature against multiple changes of 0.01 M Tris-acetate, pH 7.5, with 0.1 M NaCl and 1.0 mM NaN3 until the optical denisty of the dialysate, monitored in the 230-300 nm range, reached 0. The lipopolysacchtride suspension was next dialyzed against water in the cold overnight. DNase (type II, Sigma Chemical Co.) was added at a concentration of 2 Kunitz units/ml, and the suspension dialyzed against repeated changes of 0.1 M NaCl with 5 mM MgSO4 and 1 mM NaN3 until the absorbance of the dialysate reached 0 in the 230-300 nm range. The lipopolysaccharide suspension was then dialyzed against cold water overnight, pronase (type V, Sigma Chemical Co.) added in a concentration of 1 Kunitz unit/100 ml, the solution dialyzed overnight against several changes of 0.01 M Tris-acetate, pH 7.5, followed by dialysis against multiple changes of cold water over several days. The lipopolysaccharide suspension was lypophilized and weighed.
Characterization of purified core glycolipid. Purified E. coli J5 core glycolipid contained <1% protein as determined by the Coomassie Blue-binding method of Bradford (21) and corroborated by amino acid analysis. Neutral sugar analysis by reverse-phase chromatography using a cation exchange resin in the Li' form with 90% ethanol as eluent (22) revealed a 1:1 ratio of heptose/glucose, trace galactose, and no detectable colitose, a unique sugar contained in the O-specific side chains of the smooth E. coli 011 1:B4 parent strain. These data confirmed an incomplete core structure corresponding to the Rc chemotype of Salmonella (1, 2). Electrophoresis in 15% sodium dodecyl sulfate polyacrylamide gel followed by silver staining (23) revealed a single, broad, fast-migrating band similar in mobility to core structures from other simultaneously run lipopolysaccharides (Fig. 1) ; regularly spaced slower migrating bands characteristic of intact smooth lipopolysaccharide (23) were absent. The purity and functional integrity of core glycolipid were confirmed in mitogenesis assays using spleen cells from high-and low-responder C3H/FeJ and C3H/Hej mice, respectively. Mitogenic responses to core glycolipid were comparable to those induced by highly purified lipopolysaccharide from the smooth E. coli K235 strain (24) . These included high responses by C3H/ FeJ spleen cells, low or absent responses by C3H/HeJ spleen cells, and complete abrogation of mitogenic activity following incubation of core glycolipid with polymyxin B.
Measurement of anti-core antibodies. IgG and IgM antibodies to purified core glycolipid were quantified using ELISA (25) . Purified E. coli J5 core glycolipid was dissolved at a concentration of 25 ,ug/ml in coating buffer (15 mM Na2CO8, 30 mM NaHCOs, 3 mM NaN3, pH 9.55) and dispensed in 50-gl aliquots into 96-well polystyrene microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA). After overnight incubation at 4°C, the glycolipid suspension was removed and the wells washed five times with phosphatebuffered saline (PBS)-Tween (0.15 M NaCl, 6 mM Na2HPO4, 1 mM KH2PO4, 3 mM NaN3, and 0.5 ml/l McLean, VA).
The assay was standardized with core-specific immunoglobulin affinity purified from high-titered human plasma on a column consisting of cyanogen bromide-activated Sepharose 4B, diaminodipropylamine spacer, and purified E. coli J5 core glycolipid ligand (26) . IgO and 1gM concentrations were determined in immunopurified material using low-level radial immunodiffusion plates (Hyland Diagnostics Div., Travenol Laboratories, Deerfield, IL). Standard curves generated for anti-core IgG and 1gM were linear over a 100-to 1,000-fold dilution range (Fig. 2) total IgG levels were also higher in acute sera from survivors compared with nonsurvivors, total IgM levels were virtually identical in the two groups (Table III) .
To assess survival as a function of preexisting antibody levels, patients were separated into high and low antibody groups on the basis of arbitrary break-points. The resulting analysis (Table IV) indicated that survival was significantly enhanced in patients with high levels of core-specific IgG and IgM. Although a similar relationship was demonstrated for total IgG, that shown for total IgM was not statistically significant.
Since antibody levels to type-specific lipopolysaccharide immunodeterminants of patients' infecting Pseudomonas strains and to toxin A also appear to predict outcome (19) , correlations were examined among these previously measured variables and those quantified in the present study. As shown in Table V , core-specific IgM was highly correlated with core-specific IgG, but the IgM isotype did not correlate closely with previously measured type-specific anti-lipopolysaccharide or anti-toxin A antibodies, or with total immunoglobulin levels. In contrast, core-specific IgG levels correlated somewhat more closely with type-specific antibodies, and with total IgG and IgM levels.
Since limited correlations between cross-reactive anti-core and noncross-reactive anti-Pseudomonas antibodies suggested their relative independence, mul- tivariate analysis was used to rank them on the basis of their ability to predict outcome. Stepwise linear discriminate analysis revealed Pseudomonas type-specific anti-lipopolysaccharide antibody levels to be the best predictor of outcome, followed closely by anticore IgM. Although other variables examined in the analysis, including anti-core IgG, anti-toxin A, and total IgG levels all correlated individually with survival, none augmented the prognostic power of typespecific antibodies in combination with anti-core IgM, which together predicted outcome accurately 73.5% of the time.
To evaluate the possibility that anti-core antibodies were merely serological markers for other recognized host-related determinants of outcome, we examined some of these risk factors in relation to anti-core antibody levels (Table VI) . In the case of anti-core IgM, the incidence of rapidly fatal underlying disease and leukopenia, and the average age of high-and low-antibody groups were virtually identical. On the other hand, patients with low levels of anti-core IgG demonstrated a somewhat higher incidence of rapidly fatal underlying disease and leukopenia, and a greater predominence of males compared with the high antibody group; none of these differences was statistically significant, however. In contrast, the levels of both IgG and IgM anti-core isotypes were significantly lower in patients who had undergone prior steroid therapy. tection against the lethal effects of Gram-negative septicemia (10, (15) (16) (17) , data were heretofore lacking that clearly implicated a specific protective antibody. Likewise, in a recent study demonstrating the efficacy of treatment of Gram-negative bacteremia and shock with human antiserum to the J5 mutant (18) , there was no significant relationship between anti-J5 antibody titers achieved in patients and subsequent outcome. On the other hand, a lower incidence of shock and death was previously reported in septic patients with high levels of naturally occurring antibodies to another rough mutant strain, Salmonella minnesota Re 595 (30) . However, despite similarities, the E. coli J5 and S. minnesota Re core glycolipids are structurally and immunologically distinct (2), and the cross-reactive antibodies they stimulate have different, albeit overlapping specificities. This is particularly notable in relation to P. aeruginosa, against which anti-J5 serum has protective activity (16), while anti-Re serum is nonreactive (5) .
In this study, we showed a striking association between high concentrations of circulating antibodies to a well-characterized preparation of E. coli J5 core glycolipid present at the onset of Pseudomonas septicemia and subsequent survival. Our finding that levels of circulating antibody reactive with J5 core glycolipid are an effective prognostic marker in Pseudomonas sepsis provides an important serological link between the known antigenic cross-reactivity of endotoxin core structures (5-7) and the protection recently observed in patients administered antiserum to the rough E. coli J5 mutant strain (18) . The present study thus identifies an important immunological marker, which correlates with protective immunity in a common form of Gramnegative septicemia. Although Ziegler's study demonstrated the clinical efficacy of an immunological approach to the treatment of Gram-negative septicemia, our assay appears to provide a practical means for measuring protective antibody. Although it might be feasible, ultimately, to define protective levels of core-specific antibodies, this may be an unrealistic expectation in view of the complex nature of bacterial virulence and host resistance. This is especially true in the case of opportunistic Gram-negative pathogens like Pseudomonas, which tend to infect severely immunocompromised patients. Nevertheless, by measuring serum levels of core-specific antibodies in susceptible individuals or groups of patients, it may be possible to anticipate the need for immunotherapy directed at circulating endotoxin. Similarly, the assay of anti-core antibodies may facilitate the development and standardization of therapeutic J5 antisera or hyperimmune globulin, and help in the assessment'of their clinical efficacy.
High serum levels of both IgG and IgM antibodies to J5 core glycolipid correlated with survival in patients with Pseudomonas septicemia. Total IgG levels showed a similar association, but total IgM concentrations were virtually identical in survivors and nonsurvivors. These findings suggested a specific protective role for anti-core IgM, while it was more difficult to distinguish the protective activity of core-specific IgG and that of IgG in general.
Since antibodies to type-specific lipopolysaccharide immunodeterminants and toxin A also appear to serve a protective role in Pseudomonas septicemia (19) , we examined the interrelationship of these antibodies and those directed to endotoxin core. Although core-specific IgG and IgM correlated moderately well, neither had a very high correlation with type-specific antibodies or those directed to toxin A. This was especially true in the case of core-specific IgM, which also correlated poorly with total immunoglobulin levels. Corespecific IgG, on the other hand, corresponded somewhat more closely with total IgG and IgM levels. The lack of strong correlations among these individual antibodies, and between core-specific IgM and total immunoglobulin levels, suggested the likelihood of independent protective activities, perhaps reflecting distinct mechanisms of protection.
The relative influence on outcome of core-specific IgG and IgM, type-specific antibodies, and total immunoglobulin levels, was further examined by stepwise discriminant analysis. This statistical procedure revealed type-specific anti-Pseudomonas antibodies to be the best prognostic indicator among those antibodies examined, followed closely by core-specific antibodies of the IgM isotype, which significantly augmented the prognostic power of the more specific antibodies. In contrast, anti-core IgG, anti-toxin A, total IgG and total IgM levels added little to the apparent protective capacity of type-specific antibodies in combination with core-specific IgM. The results of this multivariate analysis were consistent with the prevailing view (9, 31) that type-specific antibodies directed at the outer, variable region of bacterial lipopolysaccharides are more protective, albeit less versatile, than cross-reacting antibodies to endotoxin core. The multivariate analysis also supported the view that anti-core IgM may have greater protective efficacy in Gram-negative septicemia compared with core-specific antibodies of the IgG isotype (18) .
Since certain host factors are critical determinants of outcome in Gram-negative sepsis (27) we examined some of these factors in relation to levels of circulating anti-core IgG and IgM present at the onset of Pseudomonas septicemia. The relatively small differences in the incidence of these host factors in high-and lowantibody groups, especially in the case of the IgM isotype, suggested that anti-core antibodies were not merely acting as serological markers for these other important risk factors. The single, rather striking exception occurred in the case of prior steroid therapy, which was significantly associated with low serum concentrations of both anti-core IgG and IgM. It is interesting to speculate that there was in fact a cause and effect relationship between these two sets of variables consistent with the reported suppressive effect of corticosteroids on antibody synthesis (32) .
Although the data presented here do not prove the protective efficacy in Pseudomonas septicemia of antibodies reactive with the endotoxin core of E. coli, they strongly suggest that possibility. Immunochemical analyses are needed to confirm and further define the structural basis for the cross-reactivity between Pseudomonas and enterobacterial lipopolysaccharide core structures implicit in our observations. Future clinical trials of J5 antiserum or hyperimmune globulin are required to confirm the clinical efficacy of these reagents and to determine whether the antibodies measured by our assay are indeed the protective factors responsible for the therapeutic success of J5 antiserum reported by Ziegler et al. (18) 
